Tag: safety profile

Robust eDNA Monitoring Finds No Significant Impact on Natural Marine Microbial Communities in Gigablue’s Field Experiment

Comprehensive eDNA analysis of open ocean experiment demonstrates minimal environmental disruption from proprietary substrate deployment

Comprehensive eDNA analysis of open ocean experiment demonstrates minimal environmental disruption from proprietary substrate deployment

HYLENR Closes Pre-Series A Funding to Commercialise Low-Energy Nuclear Reaction Systems

The Pre-Series A Funding Marks Transition from Breakthrough Research to Prototyping, Validates LENR as a Scalable Clean Energy Alternative HYDERABAD, India, Aug. 6, 2025 /PRNewswire/...

HYLENR Closes Pre-Series A Funding to Commercialise Low-Energy Nuclear Reaction Systems

The Pre-Series A Funding Marks Transition from Breakthrough Research to Prototyping, Validates LENR as a Scalable Clean Energy Alternative HYDERABAD, India, Aug. 6, 2025 /PRNewswire/...

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced that the U.S....

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS)...

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911,...

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsSafety profile

Hisense Brings Smarter Home Experiences to Families During the FIFA World Cup 2026™

Delta Thailand Highlights Integrated Smart and Green Manufacturing Solutions for Intelligent Factory Operations at Manufacturing Expo 2026

Clean Express Auto Wash Withdraws Application for Shaker Square Location

Tag: safety profile

Robust eDNA Monitoring Finds No Significant Impact on Natural Marine Microbial Communities in Gigablue’s Field Experiment

HYLENR Closes Pre-Series A Funding to Commercialise Low-Energy Nuclear Reaction Systems

HYLENR Closes Pre-Series A Funding to Commercialise Low-Energy Nuclear Reaction Systems

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us